AGENUS INC (AGEN): restructuring charge — Agenus strategic realignment: 60% annual cost cut, $100M cash burn target, workforce reduction

AGENUS INC

Agenus will reduce annual expenditures by 60% and target a cash burn of $100 million for fiscal year 2025.
Workforce reduction with severance costs estimated at approximately $1.1 million; charges expected in Q1 2025.
Company will focus resources on lead program botensilimab/balstilimab (BOT/BAL) for MSS CRC and other cancers.
Agenus secured a $22M mortgage on real estate assets to support operational flexibility during restructuring.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

AGENUS INC announced a restructuring with charges of approximately $1.1 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (reducing its workforce).

Type: restructuring
Charge: approximately $1.1 million
Affected area: Agenus Inc. (excluding its independently operating subsidiaries)
Headcount: reducing its workforce

Exact text from the filing

Costs associated with the workforce reduction are primarily severance payments and are estimated at approximately $1.1 million.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-133532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.